EGM Result and Trading Update

RNS Number:4873L
Cytomyx Holdings PLC
25 April 2005


For immediate release                                              25 April 2005



                              CYTOMYX HOLDINGS PLC
                          ("Cytomyx" or the "Company")

           Result of Extraordinary General Meeting and Trading Update

Cytomyx Holdings plc (AIM: CYX), a leading provider of drug discovery products
and services, is pleased to announce that all of the resolutions at the EGM of
the Company, held today, were duly passed.

The EGM was in respect of proposals to increase the Company's authorised share
capital and to renew its ability to issue new ordinary shares without seeking
shareholder approval or having to offer them pre-emptively.

At the EGM, the Chairman, Dr. Bill Mason, made the following statement: "During
the past month we have completed the important acquisition of the Biorepository
Business of Ardais Corporation. This was an important strategic development for
the Company and secures our position as a leader in the provision of biological
services using human clinical samples in the emerging field of translational
medicine. The acquisition has allowed us to rationalise our existing US
operation into a superior laboratory facility in Lexington, Massachusetts.

"Recent appointments to the Board and the executive management have strengthened
the commercial team and our ability to access key clients in the industry.

"Acquisition and restructuring expenditure has resulted in higher than expected
costs within the Company. In addition, sales in the second quarter from the US
operation were below budget due to the relocation. As a result the consolidated
Company loss for the first six months is expected to be higher than anticipated.

"The Company is positive about its future trading prospects, particularly in
light of the recent US acquisition and the launch of its new IonScreen (TM) drug
screening service based in the UK, both of which are being offered to clients in
the pharmaceutical industry on a global basis."

For further information, please contact:

Cytomyx Holdings plc                                         +44 (0) 1223 508191
Mike Kerins, Chief Executive

Buchanan Communications                                     +44 (0) 20 7466 5000
Mark Court/Mary-Jane Johnson

The Wall Street Group                                            +1 212 888 4848
Ron Stabiner

Notes for editors

About Cytomyx Holdings plc

Cytomyx Holdings plc is a rapidly growing life science company based in
Cambridge, UK. The Company's primary focus is on developing novel technologies
that assist pharmaceutical and biotechnology companies in their efforts to
develop new treatments more effectively. This it does by providing solutions
that provide early insights into the likely efficacy and safety profile of new
drugs in development. The Company has two main areas of expertise: the use of
human clinical samples in understanding the linkage between gene expression and
disease and the development of cell-based assays that are used to predict
potential toxicity in new drugs.  Cytomyx is listed on the AIM market of the
London Stock Exchange (CYX.L). For more information visit
www.cytomyx-holdings.com






                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

MSCBUGDSCSDGGUU

Cytomyx (LSE:CYX)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024